Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study

Cancer

Volumn 120, Issue 11, 2014, Pages 1686-1694

  McQuilten, Zoe K ^a,b   Wood, Erica M ^a   Polizzotto, Mark N ^a   Campbell, Lynda J ^c,d   Wall, Meaghan ^c   Curtis, David J ^a   Farrugia, Helen ^e   McNeil, John J ^a   Sundararajan, Vijaya ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Royal Parade   (Australia)

Author keywords

cancer registries; incidence; myelodysplastic syndromes; secondary malignancies

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CANCER REGISTRY; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; RESOURCE MANAGEMENT; VERY ELDERLY;

CANCER REGISTRIES; INCIDENCE; MYELODYSPLASTIC SYNDROMES; SECONDARY MALIGNANCIES;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTRIES;

EID: 84901296222     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28641     Document Type: Article

References (42)

1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112: 45-52.
2. Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M,. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012; 52: 2131-2138.
3. Fritz A, Percy C, Jack A, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
4. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG,. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994; 87: 743-745.
5. Maynadie M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996; 74: 288-290.
6. Germing U, Strupp C, Kündgen A, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004; 89: 905-910.
7. Australian Institute of Health and Welfare (AIHW) 2010. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra, Australia: AIHW; 2010.
8. Rodger EJ, Morison IM,. Myelodysplastic syndrome in New Zealand and Australia. Intern Med J. 2012; 42: 1235-1242.
9. Cogle CR, Craig BM, Rollison DE, List AF,. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011; 117: 7121-7125.
10. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol. 2010; 28: 2847-2852.
11. McQuilten ZK, Polizzotto MN, Wood EM, Sundararajan V,. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. Transfusion. 2013; 53: 1714-1721.
12. Hook EB, Regal RR,. Capture-recapture methods in epidemiology: methods and limitations. Epidemiol Rev. 1995; 17: 243-264.
13. Australian Bureau of Statistics (ABS), 2003. 3201.0 Population by Age and Sex, Australian States and Territories. 2001 Census Edition. Canberra, Australia: ABS. http://www.abs.gov.au/ausstats/abs@nsf/mf/3201.0. Accessed March 1, 2014.
14. Australian Institute of Health and Welfare (AIHW) 2008. Cancer in Australia: an overview, 2008. Catalog no. CAN 42. Canberra, Australia: AIHW. http://www.aihw.gov.au/publication-detail/?id=6442468196. Accessed March 1, 2014.
15. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification. 5th ed. National Centre for Classification in Health (Sydney), Faculty of Health Sciences, The University of Sydney, Australia; 2006.
16. The Australian Classification of Health Interventions (ACHI). 5th ed. National Centre for Classification in Health (Sydney), Faculty of Health Sciences, The University of Sydney, Australia; 2006.
17. Henderson T, Shepheard J, Sundararajan V,. Quality of diagnosis and procedure coding in ICD-10 administrative data. Med Care. 2006; 44: 1011-1019.
18. Delea TE, Hagiwara M, Phatak PD,. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009; 25: 139-147.
19. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-3510.
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139.
21. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA,. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004; 57: 1288-1294.
22. Clothier HJ, Vu T, Sundararajan V, et al. Invasive pneumococcal disease in Victoria: a better measurement of the true incidence. Epidemiol Infect. 2008; 136: 225-231.
23. Tilling K, Sterne JA,. Capture-recapture models including covariate effects. Am J Epidemiol. 1999; 149: 392-400.
24. Tilling K, Sterne JA, Wolfe CD,. Estimation of the incidence of stroke using a capture-recapture model including covariates. Int J Epidemiol. 2001; 30: 1351-1359.
25. McClish D, Penberthy L,. Using Medicare data to estimate the number of cases missed by a cancer registry: a 3-source capture-recapture model. Med Care. 2004; 42: 1111-1116.
26. Phekoo KJ, Richards MA, Møller H, Schey SA,. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006; 91: 1400-1404.
27. Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res. 2011; 35: 1591-1596.
28. Ma X, Does M, Raza A, Mayne ST,. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109: 1536-1542.
29. De Roos AJ, Deeg HJ, Onstad L, et al. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol. 2010; 85: 765-770.26. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
30. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951.
31. Wang R, Gross CP, Halene S, Ma X,. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009; 33: 1594-1598.
32. Nachtkamp K, Kundgen A, Strupp C, et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 2009; 33: 1024-1028.
33. Codispoti KE, Depalma L,. Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis. Int J Lab Hematol. 2010; 32: 443-448.
34. Abel GA, Friese CR, Magazu LS, et al. Delays in referral and diagnosis for chronic hematologic malignancies: a literature review. Leuk Lymphoma. 2008; 49: 1352-1359.
35. Sekeres MA,. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010; 24: 287-294.
36. Ma X,. Epidemiology of myelodysplastic syndromes. Am J Med. 2012; 125 (7 suppl): S2-S5.
37. Godley LA, Larson RA,. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35: 418-429.
38. Craig BM, Rollison DE, List AF, Cogle CR,. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res. 2011; 35: 1453-1456.
39. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA,. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999; 23: 953-959.
40. Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A,. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013; 53: 710-715.
41. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K,. Epidemiology of sepsis in Victoria, Australia. Crit Care Med. 2005; 33: 71-80.
42. Warlick ED,. Epidemiology of myelodysplastic syndromes: many questions remain. Leuk Lymphoma. 2011; 52: 163-164.